Simpler tests could slash biosimilar costs, widen patient access
A supervisor inspects pre-filled syringes of a biosimilar of Adalimumab at a Zydus Group facility in Changodar, Gujarat, 2014. The biosimilar is used to treat rheumatoid arthritis. | Photo Credit: AFP Most of the drugs that we consume are called ‘small molecule drugs’. Their chemical structure is reasonably simple. Disprin, for instance, has a molecular … Read more